WHAT IS CLAIMED IS:

1. An isolated and/or recombinant monoclonal antibody, wherein the antibody or antibody fragment is a 1H12 antibody or antibody fragment thereof comprising clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.

2. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences according to clone-paired sequences from Table 1.

3. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 70%, 80%, or 90% identity to clone-paired sequences from Table 1.

4. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 95% identity to clone-paired sequences from Table 1.

5. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 2.

6. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment comprises light and heavy chain variable sequences having 95% identity to clone-paired sequences from Table 2.

7. The monoclonal antibody of claim 1, wherein the antibody fragment is a recombinant ScFv (single chain fragment variable) antibody, Fab fragment, $F(ab')_2$ fragment, or Fv fragment.

8 The monoclonal antibody of claim 1, wherein said antibody is a chimeric antibody, or is bispecific antibody that targets a Chikungunya virus antigen other than glycoprotein.

9. The monoclonal antibody of claim 1, wherein said antibody is an IgG.

10. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment further comprises a cell penetrating peptide and/or is an intrabody.

11. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment comprises:

- a CDRH1 consisting of SEQ ID NO: 103;
- a CDRH2 consisting of SEQ ID NO: 104;
- a CDRH3 consisting of SEQ ID NO: 105;
- a CDRL1 consisting of SEQ ID NO: 187;
- a CDRL2 consisting of SEQ ID NO: 188;
- a CDRL3 consisting of SEQ ID NO: 189.

12. The monoclonal antibody of claim 1, wherein the variable region of its heavy chain comprises or consists of SEQ ID NO: 53 and the variable region of its light chain comprises or consists of SEQ ID NO: 54.

13. A hybridoma encoding an antibody or antibody fragment according to claims 1-10.

14. A method of detecting a Chikungunya virus infection in a subject comprising:

(a) contacting a sample from said subject with an antibody or antibody fragment of claims 1-12; and

(b) detecting Chikungunya virus glycoprotein E2 in said sample by binding of said antibody or antibody fragment to E2 in said sample.

15. The method of claim 14, wherein said sample is a body fluid.

16. The method of claim 14, further comprising performing steps (a) and (b) a second time and determining a change in the E2 levels as compared to the first assay.

17. Use of an antibody or antibody fragment according to claims 1-12 in the manufacture of a medicament for treating a subject infected with Chikungunya virus, or reducing the likelihood of infection of a subject at risk of contracting Chikungunya virus.

18. The use of claim 17, wherein said medicament is to be administered prior to infection.

19. The use of claim 17, wherein said medicament is to be administered after infection.

20. The use of claim 17, wherein said medicament further comprises antibody or antibody fragment administration, or genetic delivery with an RNA or DNA sequence or vector encoding the antibody or antibody fragment.

21. A pharmaceutical composition comprising the isolated and/or recombinant monoclonal antibody or antibody fragment according to claims 1-12.

22. A cell line producing the isolated and/or recombinant monoclonal antibody or antibody fragment according to claims 1-12.

23. A method of producing the isolated and/or recombinant monoclonal antibody or antibody fragment according to claims 1-12 wherein said method comprises the step of:

(a) culturing a cell line producing said isolated and/or recombinant monoclonal antibody or antibody fragment;

(b) purifying the produced isolated and/or recombinant monoclonal antibody or antibody fragment; and optionally

(c) formulating said isolated and/or recombinant monoclonal antibody or antibody fragment into a pharmaceutical composition.

24. An isolated and/or recombinant monoclonal antibody, wherein the antibody or antibody fragment is obtainable by the method of claim 23.

25. A kit comprising one isolated and/or recombinant monoclonal antibody or antibody fragment according to claims 1-12 and optionally packaging material.